Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.13 | 0.7 |
mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.027 | 0.7 |